Publications by authors named "Donna Hogge"

81Publications

Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.

Clin Lymphoma Myeloma Leuk 2020 Jul 26;20(7):e427-e436. Epub 2020 Feb 26.

Leukemia/Bone Marrow Transplant Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.02.012DOI Listing
July 2020

Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.

Clin Lymphoma Myeloma Leuk 2019 12 9;19(12):784-790. Epub 2019 Oct 9.

Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, BC Cancer, Vancouver, BC, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.09.619DOI Listing
December 2019

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 09 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.

Biol Blood Marrow Transplant 2018 06 20;24(6):1209-1215. Epub 2018 Feb 20.

Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/BMT Program of BC, BC Cancer Agency, Vancouver, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.02.007DOI Listing
June 2018

Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.

Anal Chem 2016 06 17;88(11):5680-8. Epub 2016 May 17.

Terry Fox Laboratory, BC Cancer Agency , 675 West 10th Avenue, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.5b04446DOI Listing
June 2016

Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia.

Br J Haematol 2016 08 21;174(4):526-35. Epub 2016 Apr 21.

Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021117PMC
August 2016

An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers.

Cancer Res 2016 Mar 1;76(5):1214-24. Epub 2016 Feb 1.

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Division of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2743DOI Listing
March 2016

Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function.

Leuk Res 2015 Jul 4;39(7):689-95. Epub 2015 May 4.

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.04.018DOI Listing
July 2015

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

Biol Blood Marrow Transplant 2015 Aug 10;21(8):1437-44. Epub 2015 Apr 10.

Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.04.005DOI Listing
August 2015

Deep profiling of multitube flow cytometry data.

Bioinformatics 2015 May 18;31(10):1623-31. Epub 2015 Jan 18.

Terry Fox Laboratory, BC Cancer Agency, Bioinformatics Graduate Program, University of British Columbia, Department of Hematopathology, Vancouver General Hospital and Faculty of Medical Genetics, University of British Columbia, Vancouver, Canada Terry Fox Laboratory, BC Cancer Agency, Bioinformatics Graduate Program, University of British Columbia, Department of Hematopathology, Vancouver General Hospital and Faculty of Medical Genetics, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://bioinformatics.oxfordjournals.org/content/early/2015/
Web Search
http://bioinformatics.oxfordjournals.org/content/early/2015/
Web Search
http://bioinformatics.oxfordjournals.org/cgi/doi/10.1093/bio
Publisher Site
http://dx.doi.org/10.1093/bioinformatics/btv008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426837PMC
May 2015

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.

Front Genet 2013 11;4:231. Epub 2013 Nov 11.

Department of Zoology, Life Sciences Institute, University of British Columbia Vancouver, BC, Canada ; Department of Statistics and Actuarial Science, Simon Fraser University Burnaby, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2013.00231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822292PMC
November 2013

Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.

Cancer Epidemiol Biomarkers Prev 2013 Oct 23;22(10):1918-20. Epub 2013 Jul 23.

Authors' Affiliations: Department of Zoology, Life Sciences Institute; Department of Medicine; Faculty of Pharmaceutical Sciences, University of British Columbia; British Columbia Cancer Agency, Vancouver; and Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-13-0671DOI Listing
October 2013

Expression of integrin α2 receptor in human cord blood CD34+CD38-CD90+ stem cells engrafting long-term in NOD/SCID-IL2Rγ(c) null mice.

Stem Cells 2013 Feb;31(2):360-71

Hematopoietic Stem Cell Laboratory, Department of Laboratory Medicine, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.1282DOI Listing
February 2013

Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.

Cancer Epidemiol Biomarkers Prev 2012 Nov 20;21(11):2118-20. Epub 2012 Sep 20.

Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-12-1037DOI Listing
November 2012

Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors.

Exp Hematol 2012 Nov 22;40(11):922-33. Epub 2012 Jul 22.

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2012.07.006DOI Listing
November 2012

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.

Leuk Res 2012 Jul 21;36(7):900-4. Epub 2012 Apr 21.

Department of Research, Nodality Inc, South San Francisco, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.02.022DOI Listing
July 2012

Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.

Cytometry B Clin Cytom 2012 Sep 4;82(5):283-94. Epub 2012 May 4.

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21028DOI Listing
September 2012

Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk 2012 Aug 4;12(4):274-9. Epub 2012 Apr 4.

Division of Laboratory Haematology, Vancouver General Hospital, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S215226501200004
Publisher Site
http://dx.doi.org/10.1016/j.clml.2012.01.003DOI Listing
August 2012

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.

Leuk Lymphoma 2012 Aug 1;53(8):1543-51. Epub 2012 Mar 1.

Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.660631DOI Listing
August 2012

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.

Leuk Lymphoma 2012 Jul 5;53(7):1321-6. Epub 2012 Mar 5.

Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.652108DOI Listing
July 2012

Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.

Cancer Res 2011 Dec 18;71(24):7628-39. Epub 2011 Oct 18.

Department of Biochemistry, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-2745DOI Listing
December 2011

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Biol Blood Marrow Transplant 2011 Jun 22;17(6):867-74. Epub 2010 Sep 22.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877679PMC
June 2011

Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.

Leuk Res 2010 Oct 2;34(10):1358-65. Epub 2010 Mar 2.

Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2010.01.006DOI Listing
October 2010

A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

Leuk Res 2010 Aug;34(8):1035-42

Terry Fox Laboratory, British Columbia Cancer Agency and Department of Medicine, University of British Columbia, 675 West 10 Ave., Vancouver, BC, V5Z 1L3 Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126090058
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2009.12.008DOI Listing
August 2010

Insights into acute myeloid leukemia via single cell network profiling.

Clin Lab Int 2010 Feb-Mar;34(1):12-15

201 Gateway Blvd., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696776PMC
January 2016

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2010 May 4;16(5):639-46. Epub 2010 Feb 4.

Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2009.11.026DOI Listing
May 2010

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Nat Med 2010 Jan 8;16(1):49-58. Epub 2009 Nov 8.

British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.2054DOI Listing
January 2010

Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.

Biologicals 2010 Jan 23;38(1):144-9. Epub 2009 Sep 23.

Cancer Research Institute, Scott & White Memorial Hospital, Temple, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biologicals.2009.08.016DOI Listing
January 2010

Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.

Exp Hematol 2009 Apr;37(4):450-60

British Columbia Cancer Research Centre, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2009.01.002DOI Listing
April 2009

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Biol Blood Marrow Transplant 2009 Feb;15(2):205-13

The Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2008.11.015DOI Listing
February 2009

Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Proc Natl Acad Sci U S A 2009 Jan 15;106(4):1187-92. Epub 2009 Jan 15.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0807057106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627806PMC
January 2009

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Leuk Lymphoma 2008 Mar;49(3):543-53

Scott & White Cancer Research Institute, Temple, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701799035DOI Listing
March 2008

MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.

Exp Hematol 2008 Apr 30;36(4):433-42. Epub 2008 Jan 30.

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2007.11.014DOI Listing
April 2008

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Biol Blood Marrow Transplant 2007 Aug 29;13(8):925-31. Epub 2007 May 29.

The Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2007.04.006DOI Listing
August 2007

Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.

Br J Haematol 2006 Jun;133(6):634-7

Division of Hematology, Leukemia/Bone Marrow Transplant Program of British Columbia, the Vancouver Hospital and Heath Science Centre, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2006.06080.xDOI Listing
June 2006

Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.

Clin Cancer Res 2006 Feb;12(4):1284-91

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2070DOI Listing
February 2006

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

Leuk Lymphoma 2005 Apr;46(4):525-31

The Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver Hospital and Health Sciences Center, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190400025112DOI Listing
April 2005

Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation.

Br J Haematol 2004 Nov;127(3):311-21

Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2004.05194.xDOI Listing
November 2004

The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.

Leuk Res 2004 Nov;28(11):1221-6

Terry Fox Laboratory, British Columbia Cancer Agency, 601 West 10th Avenue, Vancouver, Canada V5Z 1L3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2004.03.015DOI Listing
November 2004

Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.

Protein Expr Purif 2004 Jan;33(1):123-33

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pep.2003.09.003DOI Listing
January 2004

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.

Blood 2004 Jan 4;103(1):333-9. Epub 2003 Sep 4.

Leukemia/Bone Marrow Transplantation (BMT), Division of Hematology, Vancouver General Hospital, Vancouver, BC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-03-0940DOI Listing
January 2004

Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.

Exp Hematol 2002 Nov;30(11):1316-23

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0301-472x(02)00925-6DOI Listing
November 2002

Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia.

Exp Hematol 2002 Jul;30(7):721-8

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0301-472x(02)00824-xDOI Listing
July 2002

Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells.

Blood 2002 Aug;100(3):862-8

Terry Fox Laboratory, British Columbia Cancer Agency, and the Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-01-0220DOI Listing
August 2002

Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia.

Mol Ther 2002 Apr;5(4):352-9

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, V5Z 1L3, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/mthe.2002.0573DOI Listing
April 2002

A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.

Cancer Res 2002 Mar;62(6):1730-6

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 1L3 Canada.

View Article

Download full-text PDF

Source
March 2002